1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > OXiGENE, Inc. - Product Pipeline Review - 2015

OXiGENE, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 36 pages

OXiGENE, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘OXiGENE, Inc. - Product Pipeline Review - 2015’, provides an overview of the OXiGENE, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OXiGENE, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of OXiGENE, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of OXiGENE, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the OXiGENE, Inc.’s pipeline products

Reasons to buy

- Evaluate OXiGENE, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of OXiGENE, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the OXiGENE, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of OXiGENE, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of OXiGENE, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of OXiGENE, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

OXiGENE, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
OXiGENE, Inc. Snapshot 5
OXiGENE, Inc. Overview 5
Key Information 5
Key Facts 5
OXiGENE, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
OXiGENE, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
OXiGENE, Inc. - Pipeline Products Glance 10
OXiGENE, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
OXiGENE, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
OXiGENE, Inc. - Drug Profiles 13
fosbretabulin tromethamine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
OXi-4503 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
KGP-156 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
KGP-18 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
KGP-94 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
OXiGENE, Inc. - Pipeline Analysis 22
OXiGENE, Inc. - Pipeline Products by Target 22
OXiGENE, Inc. - Pipeline Products by Route of Administration 23
OXiGENE, Inc. - Pipeline Products by Molecule Type 24
OXiGENE, Inc. - Pipeline Products by Mechanism of Action 25
OXiGENE, Inc. - Recent Pipeline Updates 26
OXiGENE, Inc. - Dormant Projects 33
OXiGENE, Inc. - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
OXiGENE, Inc., Key Information 5
OXiGENE, Inc., Key Facts 5
OXiGENE, Inc. - Pipeline by Indication, 2015 7
OXiGENE, Inc. - Pipeline by Stage of Development, 2015 8
OXiGENE, Inc. - Monotherapy Products in Pipeline, 2015 9
OXiGENE, Inc. - Phase II, 2015 10
OXiGENE, Inc. - Phase I, 2015 11
OXiGENE, Inc. - Preclinical, 2015 12
OXiGENE, Inc. - Pipeline by Target, 2015 22
OXiGENE, Inc. - Pipeline by Route of Administration, 2015 23
OXiGENE, Inc. - Pipeline by Molecule Type, 2015 24
OXiGENE, Inc. - Pipeline Products by Mechanism of Action, 2015 25
OXiGENE, Inc. - Recent Pipeline Updates, 2015 26
OXiGENE, Inc. - Dormant Developmental Projects,2015 33

List of Figures
OXiGENE, Inc. - Pipeline by Top 10 Indication, 2015 7
OXiGENE, Inc. - Pipeline by Stage of Development, 2015 8
OXiGENE, Inc. - Monotherapy Products in Pipeline, 2015 9
OXiGENE, Inc. - Pipeline by Top 10 Target, 2015 22
OXiGENE, Inc. - Pipeline by Top 10 Route of Administration, 2015 23
OXiGENE, Inc. - Pipeline by Top 10 Molecule Type, 2015 24
OXiGENE, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.